This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
home:diseases:ankylosing_spondylitis [01.11.2019] – [Standard treatments] sallieq | home:diseases:ankylosing_spondylitis [09.14.2022] (current) – external edit 127.0.0.1 | ||
---|---|---|---|
Line 4: | Line 4: | ||
====== Ankylosing spondylitis ====== | ====== Ankylosing spondylitis ====== | ||
- | ===== Introduction ===== | + | < |
- | //from// [[https:// | + | |
+ | |||
+ | //from// [[https:// | ||
A form of arthritis, AS is characterized by chronic inflammation, | A form of arthritis, AS is characterized by chronic inflammation, | ||
Line 24: | Line 26: | ||
[[https:// | [[https:// | ||
- | ==== Standard treatments | + | ==== Immune suppression |
Injections used in standard medical treatment are seriously immune suppressant | Injections used in standard medical treatment are seriously immune suppressant | ||
Line 40: | Line 42: | ||
He experienced waxing and waning of symptoms both physical and emotional through the first 3 years of treatment, peaking in mid 2007. Presently he is no longer depressed and is back working full time in international finance. His prostatitis has cleared as has his IBS. Bone density increased 11% in his femur and 5% in his lumbar vertebrae over the last 2 years. His Bath Ankylosing spondylitis Disease Activity Index which had risen from 8.8 to 9.2 is now 5.3.</ | He experienced waxing and waning of symptoms both physical and emotional through the first 3 years of treatment, peaking in mid 2007. Presently he is no longer depressed and is back working full time in international finance. His prostatitis has cleared as has his IBS. Bone density increased 11% in his femur and 5% in his lumbar vertebrae over the last 2 years. His Bath Ankylosing spondylitis Disease Activity Index which had risen from 8.8 to 9.2 is now 5.3.</ | ||
- | |||
- | |||
- | {{tag> | ||
- | |||
Line 60: | Line 58: | ||
CONCLUSION: The role of K. pneumoniae and anti-collagen antibodies in the aetiopathogenesis of CD and AS requires further study. | CONCLUSION: The role of K. pneumoniae and anti-collagen antibodies in the aetiopathogenesis of CD and AS requires further study. | ||
- | (({{pubmed> | + | (({{pmid> |
+ | [[https:// | ||
===== Management ===== | ===== Management ===== | ||
- | The prevalence rate of hip involvement in AS patients varies from 10 to 23%, depending on the type of hip assessment. TNF-α blocking therapy significantly improved tender hip joints, and inflammatory US lesions including positive power Doppler. | + | The prevalence rate of hip involvement in AS patients varies from 10 to 23%, depending on the type of hip assessment. TNF-α blocking therapy significantly improved tender hip joints, and inflammatory US lesions including positive power Doppler. |
Line 70: | Line 69: | ||
Patients with ankylosing spondylitis (AS) warrant a comprehensive clinical assessment because of the lack of biomarkers of disease activity, prognosis and response to biologic therapy. Multiple AS-related questionnaires have been developed to assess the disease status accurately, but feasibility remains a problem in clinical practice. | Patients with ankylosing spondylitis (AS) warrant a comprehensive clinical assessment because of the lack of biomarkers of disease activity, prognosis and response to biologic therapy. Multiple AS-related questionnaires have been developed to assess the disease status accurately, but feasibility remains a problem in clinical practice. | ||
- | The Bath Ankylosing Disease Activity Index remains the gold standard for assessing disease activity in a routine practice, despite poor correlation with C-reactive protein (CRP) levels and MRI inflammation. | + | The Bath Ankylosing Disease Activity Index remains the gold standard for assessing disease activity in a routine practice, despite poor correlation with C-reactive protein (CRP) levels and MRI inflammation. |
- | ==== Headline ==== | ||
- | < | ||
- | |||
- | I do fair better with fortified calcium foods than I do calcium supplements! | ||
==== TNF inhibitor dose ==== | ==== TNF inhibitor dose ==== | ||
- | In patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses. | + | In patients with ankylosing spondylitis in clinical remission for at least 6 months, dose reduction is non-inferior to full TNF inhibitor doses to maintain LDA after 1 year. Serious adverse events may be less frequent with reduced doses. |
Line 89: | Line 84: | ||
< | < | ||
+ | ==== D-free calcium ==== | ||
- | ==== Related research ==== | + | < |
- | The findings from this study indicated that even short-term oral use of alendronate led to ONJ in a subset | + | I do fair better with fortified calcium foods than I do calcium supplements! |
- | Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw | ||
- | + | ==== Related research on osteonecrosis ==== | |
+ | The findings from this study indicated that even short-term oral use of alendronate led to ONJ in a subset of patients after certain dental procedures were performed. These findings have important therapeutic and preventive implications. | ||
- | {{tag>diseases arrange}} | + | Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw (({{pmid>long: |
+ | |||
+ | {{tag> | ||
+ | < | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
Line 119: | Line 118: | ||
< | < | ||
- | Time to prove the infective etiology of ankylosing spondylitis and related spondylarthritides: | + | Time to prove the infective etiology of ankylosing spondylitis and related spondylarthritides: |
Zeidler H, Rihl M. | Zeidler H, Rihl M. | ||
Line 157: | Line 156: | ||
</ | </ | ||
- | ===== References ===== | + | ===== References =====</ |